Karamali Maryam, Eghbalpour Sara, Rajabi Sajad, Jamilian Mehri, Bahmani Fereshteh, Tajabadi-Ebrahimi Maryam, Keneshlou Fariba, Mirhashemi Seyyed Mehdi, Chamani Maryam, Hashem Gelougerdi Sara, Asemi Zatollah
Department of Gynecology and Obstetrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Research Center, Department of Gynecology and Obstetrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Arch Iran Med. 2018 Jan 1;21(1):1-7.
To the best of our knowledge, data on effects of probiotic administration on hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome (PCOS) are scarce. This investigation was conducted to assess the effects of probiotic supplementation on hormonal profiles, biomarkers of inflammation and oxidative stress in women with PCOS.
This randomized, double-blind, placebo-controlled trial was conducted on 60 women with PCOS, aged 18-40 years old. Subjects were randomly assigned into 2 groups to receive either probiotics or placebo (n = 30 each group) for 12 weeks. Metabolic profiles were quantified at baseline and after a 12-week intervention.
After the 12-week intervention, compared with placebo, probiotic supplementation significantly increased serum sex hormone-binding globulin (SHBG) (+25.9 ± 32.5 vs. +0.5 ± 15.6 nmol/L, P < 0.001) and plasma total antioxidant capacity (TAC) (+8.8 ± 120.5 vs. -98.3 ± 246.4 mmol/L, P = 0.04), and significantly decreased serum total testosterone (-0.2 ± 0.7 vs. +0.2 ± 0.6 ng/mL, P = 0.03), modified Ferriman-Gallwey (mF-G) scores (-1.7 ± 1.5 vs. -0.2 ± 1.0, P < 0.001), serum high-sensitivity C-reactive protein (hs-CRP) (-1150.0 ± 1295.2 vs. +202.5 ± 1426.3 ng/mL, P < 0.001) and plasma malondialdehyde (MDA) concentrations (-0.2 ± 0.6 vs. +0.9 ± 1.3 µmol/L, P < 0.001). We did not observe any detrimental effect of probiotic supplementation on other metabolic profiles.
Overall, probiotic supplementation of PCOS women for 12 weeks had beneficial effects on total testosterone, SHBG, mFG scores, hs-CRP, TAC and MDA levels but did not affect other metabolic profiles.
据我们所知,关于益生菌给药对多囊卵巢综合征(PCOS)女性激素水平、炎症和氧化应激生物标志物影响的数据很少。本研究旨在评估补充益生菌对PCOS女性激素水平、炎症和氧化应激生物标志物的影响。
本随机、双盲、安慰剂对照试验对60名年龄在18 - 40岁的PCOS女性进行。受试者被随机分为两组,分别接受益生菌或安慰剂治疗(每组n = 30),为期12周。在基线和12周干预后对代谢指标进行量化。
12周干预后,与安慰剂组相比,补充益生菌显著提高了血清性激素结合球蛋白(SHBG)水平(分别为+25.9 ± 32.5 vs. +0.5 ± 15.6 nmol/L,P < 0.001)和血浆总抗氧化能力(TAC)(分别为+8.8 ± 120.5 vs. -98.3 ± 246.4 mmol/L,P = 0.04),并显著降低了血清总睾酮水平(分别为-0.2 ± 0.7 vs. +0.2 ± 0.6 ng/mL,P = 0.03)、改良费里曼-盖尔维(mF-G)评分(分别为-1.7 ± 1.5 vs. -0.2 ± 1.0,P < 0.001)、血清高敏C反应蛋白(hs-CRP)水平(分别为-1150.0 ± 1295.2 vs. +202.5 ± 1426.3 ng/mL,P < 0.001)和血浆丙二醛(MDA)浓度(分别为-0.2 ± 0.6 vs. +0.9 ± 1.3 µmol/L,P < 0.001)。我们未观察到补充益生菌对其他代谢指标有任何有害影响。
总体而言,PCOS女性补充益生菌12周对总睾酮、SHBG、mFG评分、hs-CRP、TAC和MDA水平有有益影响,但不影响其他代谢指标。